Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
OpenAI in talks with Samsung to power AI features, report says
-
4
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
S. Korea not to attend Sado mine memorial: foreign ministry
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
Celltrion, a local bio company, on Monday had its biosimilar for an antibody against arthritis approved.
This is the first time an antibody copy treatment was approved in the world, the company said.
The Korea Food and Drug Administration on Monday authorized “Remsima,” a biosimilar of Janssen’s “Remicade.” The company has conducted clinical trials on a total of 856 patients from 29 countries.
The drug maker said Remsima could replace Remicade for use for rheumatic arthritis, ankylosing spondylitis, psoriasis and other conditions.
This is the first time an antibody copy treatment was approved in the world, the company said.
The Korea Food and Drug Administration on Monday authorized “Remsima,” a biosimilar of Janssen’s “Remicade.” The company has conducted clinical trials on a total of 856 patients from 29 countries.
The drug maker said Remsima could replace Remicade for use for rheumatic arthritis, ankylosing spondylitis, psoriasis and other conditions.
-
Articles by Korea Herald
